According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Several other equities analysts have also recently commented on HLUYY. Barclays reiterated an “overweight” rating on shares of H. Lundbeck A/S in a research note on Monday, March 8th. Credit Suisse Group reiterated an “underperform” rating on shares of H. Lundbeck A/S in a research note on Friday, March 26th. Bank of America upgraded shares of H. Lundbeck A/S from an “underperform” rating to a “neutral” rating in a research note on Friday, February 12th. Finally, JPMorgan Chase & Co. raised shares of H. Lundbeck A/S from a “neutral” rating to an “overweight” rating in a report on Friday, February 5th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $47.00.
H. Lundbeck A/S Company Profile
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; Vyepti for migraine prevention; and Rexulti to treat depression/schizophrenia.
Featured Story: What is a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.